Cite
SAT-283-Plasma acylcarnitines are biomarkers of magnetic resonance imaging-proton density fat fraction response in NASH patients treated with the ACC inhibitor GS-0976.
MLA
Charlton, Michael, et al. “SAT-283-Plasma Acylcarnitines Are Biomarkers of Magnetic Resonance Imaging-Proton Density Fat Fraction Response in NASH Patients Treated with the ACC Inhibitor GS-0976.” Journal of Hepatology, vol. 70, Apr. 2019, pp. e758–59. EBSCOhost, https://doi.org/10.1016/S0618-8278(19)31515-4.
APA
Charlton, M., Lai, M., Noureddin, M., Tarrant, J. M., Hu, T., Chen, G., Mccolgan, B., Chung, C., Chuang, J., Patterson, S. D., Myers, R., Mantry, P., Ruane, P., & Loomba, R. (2019). SAT-283-Plasma acylcarnitines are biomarkers of magnetic resonance imaging-proton density fat fraction response in NASH patients treated with the ACC inhibitor GS-0976. Journal of Hepatology, 70, e758–e759. https://doi.org/10.1016/S0618-8278(19)31515-4
Chicago
Charlton, Michael, Michelle Lai, Mazen Noureddin, Jacqueline M. Tarrant, Tao Hu, Guang Chen, Bryan Mccolgan, et al. 2019. “SAT-283-Plasma Acylcarnitines Are Biomarkers of Magnetic Resonance Imaging-Proton Density Fat Fraction Response in NASH Patients Treated with the ACC Inhibitor GS-0976.” Journal of Hepatology 70 (April): e758–59. doi:10.1016/S0618-8278(19)31515-4.